Find and Pitch Jounalists, Get Your Story Covered

Tags: smart home wi-fi shopping buying guides routers

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Add-On Cemiplimab Shows Promise as First-Line Treatment for Penile Cancer - 17 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 6 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 8 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 11 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - over 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - over 1 year ago
2	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Adding Palbociclib to Standard Care Improved PFS in Triple-Positive Breast Cancer - about 2 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 8 months ago Regorafenib-Pembrolizumab Has 'Modest' Activity in HCC Post-Immunotherapy - 9 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - about 1 year ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - over 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - over 1 year ago New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis - over 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis - 3 months ago MHRA grants approval for bladder cancer drug erdafitinib - 4 months ago
4	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia - 3 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - over 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - over 1 year ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 3 months ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 7 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 11 months ago FDA Accepts Application, Grants Priority Review to Vorasidenib for IDH-Mutant Diffuse Glioma - about 1 year ago
6	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 4 months ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 4 months ago
7	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 6 months ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 7 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 8 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - about 1 year ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - over 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - over 1 year ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 7 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - about 1 year ago
10	Ryan Haumschild, PharmD, MS, MBA Pharmacy Times Director of Pharmacy. Editorial Board member. Atlanta, Georgia pharmacyhealthcareeditorial workadvisory	Alternative Treatments for eBC and mBC - 9 months ago Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment - over 1 year ago NCCN Guidelines on CDK4/6 Inhibitor Treatment Regimens - over 1 year ago Differentiating Between Adverse Event Profiles of Various CDK4/6 Inhibitors - over 1 year ago Progression-Free Survival and Overall Survival Associated With CDK4/6 Inhibitor Therapy - over 1 year ago

Journalists covering CDK4/6 inhibitor therapy